1

BY KAILAS NADEKARPM/2012/408

2

HISTORY• It is a British-Swedish multinational pharmaceutical and biologics company

headquartered in London, United Kingdom. It is the world's fifth-largest pharmaceutical company measured by 2009

• It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation

• The company was founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group.

• AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalization of approximately £39.5 billion as of 23 December 2011, the tenth-largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange.

• Astra AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries. In 1993 the British chemicals company ICI demerged its pharmaceuticals businesses and its agrochemicals and specialties businesses, to form Zeneca Group plc,.Finally, in 1999 Astra and Zeneca Group merged to form AstraZeneca plc

3

Major acquisition• In 2005 the company announced that it had become a Diamond Member of

the Pennsylvania Bio commerce organisation. It also acquired KuDOS Pharmaceuticals, a UK biotech company, for £120m and entered into an anti-cancer collaboration agreement with Astex.

• In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology for £702 million.

• In February 2007 AstraZeneca agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti-viral therapies, for $150 million.

• AstraZeneca's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to pipeline-boosting collaboration and acquisition activities. A few days later AstraZeneca acquired American company MedImmune for about $15.2 billion; AstraZeneca subsequently consolidated all of its biologics operations into a dedicated biologics division called MedImmune.

4

Cont…..• In 2011 AstraZeneca acquired Guangdong BeiKang Pharmaceutical

Company, a Chinese generics business.• In February 2012 AstraZeneca and Amgen announced collaboration on

treatments for inflammatory diseases.Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion.

• In June 2012 AstraZeneca and Bristol-Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals. It was agreed that Bristol-Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying $3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between AstraZeneca and Bristol-Myers Squibb. dapagliflozin, new patent in USA

5

MANAGEMENT TEAM

• Leif Johansson (chairman) Pascal Soriot (CEO)

SINCE FROM OCT 2012SINCE FROM April 2012

6

Blockbuster drugs of AstraZeneca

• Gastrointestinal - Prilosec and Nexium• Cardiovascular - Crestor, Seloken &

Atacand• Neuroscience – Seroquel• Cancer - Arimidex, Casodex & Zoladex • Respiratory - Symbicort & Pulmicort

7

Seroquel• Seroquel, manufactured by AstraZeneca, lost its marketing exclusivity

on March 26, 2012. an analyst investor said the loss of the drug's patent could mean a loss of $4.3 billion for the company - nearly half of its total pretax profit. Despite disagreeable side effects, like weight gain and diabetes, the drug pulled in approximately $5.3 billion in revenue in 2010, and as a whole, AstraZeneca walked away with $33.3 billion. Experts agree the patent expiry shouldn't affect AstraZeneca too much; Seroquel is about 13 percent of the company's revenues. Still, the drug is "enormously profitable," said Berstein Research's Tim Anderson, in a meeting following the company's Q4 earnings call. "AZN faces many big patent expiries between 2010 and 2015, such as Seroquel (U.S. expiry early 2012), product with pretax margins greater than 80 percent

8

AstraZeneca in India• 1979 -Astra collaborates with IDL to set up manufacturing and marketing

base in India.• 1985-Government of India permitted ASTRA AB to set-up a R&D Unit as a

non-profit society with 50% representation of Astra and 50% representation of Government of India on the Governing Board.

• 1987-Astra Research Centre India (ARCI) was set up in a building leased from IDL Chemicals Ltd. at Malleswaram Bangalore

• 1997-Government of India permitted Astra AB to form 100% owned company (Astra Biochemicals Pvt. Ltd )

• 1999-Astra Research Centre India was renamed AstraZeneca Research Foundation India to reflect its affiliation with the new company resulting from the merger of Astra and Zeneca.

9

AstraZeneca in India

• AstraZeneca in India has its Research and Development,Manufacturing and Marketing offices in Bangalore,operating through two companies:

• 1-AstraZeneca Parma India Limited (AZPIL), involved in Manufacturing and Marketing, and

• 2- AstraZeneca India Private Limited (AZIPL),involved in Research and Development,Pharmaceutical Research & Development and Branded Generics

10

Work culture of company

• They believe that the best way to offer innovative healthcare solutions for the global community is to work with others in that community. So They work with partners who complement our existing skills, enhance their internal innovation and bring extra value to what They do. By sharing ideas and exchanging information, They can enhance their creativity and effectiveness.

• They like to engage with doctors, patients and other stakeholders, so They’re in a better position to understand their needs and the issues they face. They also have a close relationship with governments and healthcare organizations to ensure their products represent value for money. And They often team up with NGOs to improve local healthcare in vulnerable communities around the world. Teamwork is at the heart of what They do. In the last three years They entered into 60 major R&D collaborations and we intend to continue this approach to help achieve their goal of better health for patients.

11

AstraZeneca partner with a number of leading health organization committed to fighting neglected diseases. 

• Entered into the ground-breaking TB Drug Accelerator (TBDA) partnership along with the Bill & Melinda Gates Foundation, six other pharmaceutical companies plus four research institutions with the aim of speeding-up the discovery of essential new treatments

• Entered into a research collaboration with the Global Alliance for TB Drug Development (TB Alliance)

• AstraZeneca is also involved in other efforts to fight TB with:• · The British Red Cross• · The International Red Cross and the Red Crescent• · The African Medical and Research Foundation (AMREF) together

with the Ministry of Health in Uganda.

12

Beyond the TB space also collaborate with:

• Medicines for Malaria Venture (MMV) allowing MMV access to AstraZeneca’s compound library to identify promising candidates with the potential to treat malaria, including drug-resistant strains

• • · The UK’s Liverpool School of Tropical Medicine’s Anti-W They

olbachia (A WOL) Consortium, as part of a research agreement ∙aimed at finding new medicines to treat river blindness and lymphatic filariasis

• • · The Drugs for Neglected Diseases initiative (DNDi) to

collaborate on drug-compound screening for three neglected tropical diseases: leishmaniasis, Chagas disease and sleeping sickness.

13

Bangalore R&D plant

Headed By Dr. Sudhir Nambiar, Vice President

14

Corporate social responsibility• Young Health Programme (YHP): AstraZeneca’s Young Health

Programme (YHP) is AstraZeneca’s Global Signature Initiative, established in partnership with Plan International and Johns Hopkins University. In India, AstraZeneca has established YHP in partnership with Plan India. YHP is a long-term community investment programme which seeks to reach one million disconnected young people to help them understand and deal with the health issues they face. The programme aligns with AstraZeneca’s goal of improving healthcare and the company’s core values and does not directly address any of the areas in which it has a commercial interest. AstraZeneca is currently the only pharmaceutical company in the world that is focused on the issue of adolescent health. AstraZeneca is doing this because health connects us all.

• In India, AstraZeneca and Plan India are currently working in 5 community sites in Delhi – Badarpur, Madanpur, Khadar, Holambi, Kalan, Dwaraka and Mangolpuri.

15

• The focussed objectives are:– Capacity building of adolescents by providing relevant information,

knowledge on lifestyles, and better choices that will help enhance responsive health seeking behavior

– Establishing community based actions on key infections – like Dengue and Malaria

– Raising awareness and knowledge about access to available health care systems

– Addressing the immediate needs of the community in issues relating to health care, hygiene and sanitation

– Reaching an estimated 30,000 adolescents and youth over the next 5 years• Other key recent initiative in India include:

– On-going support in the areas of health, infrastructure & education for a needy government school in Katigenahalli village, Yelahanka, close to the Bangalore manufacturing unit.

– Sanjeevini Comprehensive Trauma Consortium is voluntary, non-profit, non-governmental organisation specialising in rendering state-of-the-art pre-hospital care to all accident and medical emergency victims throughout the country, AstraZeneca is providing on-going support for Ambulance service since 2006

16